Bayer Healthcare’s pharmaceuticals division has certainly had its ups and downs, and some ultra-tense relationships with partners—notabl...

FivePrime Therapeutics has a new CEO. As of Wednesday, August 17, the next-generation antibody company is listing its founder Lewis Williams...

From out of the mists of confusion created by the European Medicines Agency’s initial ineptitude in seeking a new head – its first job adver...

Whilst countries in the Middle East struggle with the concept of the democratic process, the French minister of health, Xavier Bertrand, is ...

Jean Marimbert’s resignation from his post as the Director General of the French medicines agency, Afssaps, carries the whiff of scapegoat...

Josh Sharfstein's departure back to the friendly Democratic climes of Maryland left HHS management and FDA Commissioner Margaret Hamburg...

Funny what drops into inboxes, isn't it? We found a copy of Ian Read's "good morning, I'm-taking-over-from-Jeff" lette...

Will it matter if Europe’s top medicines regulator, the European Medicines Agency (EMA), is without an Executive Director for the next six m...

It's always fun to read between the lines--and put in a few calls--when CEOs depart over 'strategic differences' with their boar...

Well, well, well. Of all the people to replace CEO Jim Mullen, the ever-more-Icahnized Biogen Idec tabbed George Scangos, the chief of Exeli...

In the immortal words of one Archie Bunker those were the days, weren’t they? Back when biotechs were biotechs (small and innovative—and usu...

There are several reasons Schering-Plough chief executive Fred Hassan sounded upbeat on the conference call this morning to discuss the $41 ...

We admit to being impressed with the smaller-is-better strategy from Bristol-Myers Squibb under CEO Jim Cornelius. He didn’t really have muc...

We just heard the news that Bob Ruffolo, Wyeth’s R&D boss, is retiring. A few points to make: first, from our auslander ’s point of view...

Sometimes we don't have the time to cover all the stories we'd like. But occasionally we'd like to link over to them anyway, whi...

At this week’s BIO-Europe meeting, Vaughn Kailian asked his panelists: why don’t biotech’s most innovative executives ever join pharma? But ...

Novartis posted its third quarter results this morning and missed its profit guidance . Genericization, delays to Galvus , and the withdrawa...

This weekend we were in Cardiff for the Rugby World Cup quarterfinal between France and New Zealand, which saw France upsetting the favorite...

Yesterday, Pfizer’s Jeff Kindler ended the speculation around what we think is his most important appointment, elevating development chief M...